Full Press Release Details
Galvin JE, Hambe ME, Iaci JF, et al. Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies . Podium presentation at 2025 Alzheimer’s Association International Conference (AAIC) ; Toronto, Ontario, Canada
CGTX Positive Sentiment
Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Key Takeaway: A Phase 2 study of CT1812 in patients with mild-to-moderate dementia with Lewy bodies was presented by Galvin et al. at the 2025 Alzheimer’s Association International Conference in Toronto. The research highlights the potential of CT1812 as a treatment option in this patient population. The presentation underscores the importance of ongoing research in dementia therapies.
Price reaction · baseline $0.7151 (2025-07-28 close) · hit pre-market · 3 other CGTX headline(s) in the window, move may be shared
day 0 close
-6.3%
day 1 · peak
-13%
day 3
-6.7%
Market Sentiment Analysis
POSITIVE FACTORS
- CT1812 shows potential in treating dementia with Lewy bodies.
- The study is part of a significant conference presentation.
- Increased attention on dementia treatments at the AAIC.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Frequently Asked Questions
What is CT1812?
CT1812 is a drug being studied for its potential to treat dementia with Lewy bodies.
Where was the study presented?
The study was presented at the 2025 Alzheimer’s Association International Conference in Toronto.
What type of dementia was the focus of the study?
The study focused on mild-to-moderate dementia with Lewy bodies.
Who conducted the study?
The study was conducted by Galvin JE, Hambe ME, Iaci JF, and others.